乐心医疗(300562.SZ)公告称，公司上半年实现营收5.21亿元，同比增长4.57%；归属于上市公司股东的 净利润为4229.04万元，同比增长21.35%。公司拟向全体股东每10股派发现金红利1.3元（含税）。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Group 1 - The core viewpoint of the article highlights that 乐心医疗 (Leksin Medical) reported its 2025 semi-annual results, showing a revenue of 521 million yuan, which represents a year-on-year growth of 4.57% [1] - The net profit attributable to shareholders of the listed company reached 42.29 million yuan, reflecting a year-on-year increase of 21.35% [1] - The company plans to distribute a cash dividend of 1.3 yuan (including tax) for every 10 shares to all shareholders [1]

（记者 王晓波） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 每经AI快讯，乐心医疗（SZ 300562，收盘价：16.96元）8月15日晚间发布半年度业绩报告称，2025年 上半年营业收入约5.21亿元，同比增加4.57%；归属于上市公司股东的净利润约4229万元，同比增加 21.35%；基本每股收益0.1945元，同比增加21.03%。 截至发稿，乐心医疗市值为37亿元。 每经头条（nbdtoutiao）——连胜之后匹配"猪队友"，连败之后则"摆烂"都能赢？中国游戏算法第一案 开庭，资深玩家与《王者荣耀》对簿公堂 ...

Core Viewpoint - 乐心医疗 announced its third board meeting of the fifth session on August 14, 2025, to review the full and summary reports for the first half of 2025 [1] Group 1: Financial Performance - For the first half of 2025, 乐心医疗's revenue composition is as follows: home medical products accounted for 66.29%, electronic health scales for 24.17%, others for 7.55%, and wearable fitness bands for 1.99% [1] - The current market capitalization of 乐心医疗 is 3.7 billion yuan [1]

来源：金融界 资料显示，乐心医疗成立于2002年，位于中山市火炬开发区东利路105号A区，是一家以从事健康IoT业 务,数字健康服务业务(健康IoT+SaaS服务模式)。为主的企业。企业注册资本2.18亿人民币，法人代表为 潘伟潮。 通过天眼查大数据分析，广东乐心医疗电子股份有限公司共对外投资了17家企业，参与招投标项目26 次；知识产权方面有商标信息434条，专利信息604条；此外企业还拥有行政许可150个。 乐心医疗半年报数据显示，2025年1-6月营业总收入为5.21亿元，较去年同期增长4.57%，净利润为 4229.04万，较去年同期增长21.35%，每股收益0.1945元，净资产收益率为4.19%，每股经营现金流量为 0.2219元，销售毛利率为35.00%，所处行业为医疗器械。 ...

乐心医疗 2025 年公告 证券代码：300562 证券简称：乐心医疗 公告编号：2025-082 广东乐心医疗电子股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《企业会计准则》《深圳证券交易所上市公司自律监管指引第 2 号—创 业板上市公司规范运作》《深圳证券交易所创业板上市公司自律监管指南第 1 号 —业务办理》等相关规定，为了真实、公允、准确地反映 2025 年半年度财务状 况和资产价值，广东乐心医疗电子股份有限公司（以下简称"公司"）对公司及 子公司相关资产进行计提减值准备和核销部分资产，现将具体情况公告如下： 一、计提资产减值准备和核销资产的范围和金额 截至 2025 年 6 月 30 日，资产减值准备期末余额为 96,794,808.56 元，具体 情况如下： 公司及子公司按会计政策对可能发生减值迹象的资产进行全面清查和资产 减值测试后，在 2025 年半年度计提/转回各项资产减值准备共 11,654,098.05 元， 核销资产减值准备共 17,949,366.89 元，具体情况如下： 单位：人民币 元 | 项目 | 期初数 ...

Summary of Key Points Core Viewpoint The report outlines the management, storage, and usage of the funds raised by Guangdong Leshi Medical Electronics Co., Ltd. for the first half of 2025, detailing the total amount raised, the current balance, and the specific projects funded. Fundraising Overview - The company raised a total of RMB 385,356,068.13 by issuing 23,998,780 shares at a price of RMB 16.48 per share to 14 specific investors [1][2] - As of the end of 2024, the balance in the fundraising special account was RMB 190,328,551.27, with RMB 9,537,660.29 used in the current year, leaving a balance of RMB 182,230,103.57 as of June 30, 2025 [2][5] Fund Management - The company has established a fundraising management system to enhance the efficiency of fund usage, complying with relevant regulations [2][3] - Funds are stored in special accounts at various banks, including China Construction Bank and Bank of China, specifically for the purpose of managing the raised funds [3][4] Fund Usage - The actual usage of the raised funds for the first half of 2025 is detailed in an attached table, with no changes in project implementation locations or methods reported [7][8] - The company has approved the use of up to RMB 180 million of idle funds for cash management, investing in safe and liquid financial products [7][8] Project Adjustments - The company has decided to extend the timeline for certain projects, such as the "Smart Blood Glucose Monitoring Product Industrialization Project," to October 31, 2026, due to market conditions and operational needs [8][10] - The remaining RMB 5,627.60 million from the "TWS Earphone Production Line Construction Project" will be used for permanent working capital [10][12] Compliance and Reporting - The company confirms that there are no issues with the disclosure of fundraising usage, and all activities comply with regulatory requirements [8][9] - The report was approved by the board of directors on August 14, 2025 [8]

公区） 网设备销售；电子产品销售；物联网技术研发；互联网数据服务；货物进出口。 （除依法须经批准的项目外，凭营业执照依法自主开展经营活动） | | | | | 乐心医疗 2025 | | | 年公告 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 单位：元 | | | | 截至 | 2025 年 | 6 月 | 30 日 | 2024 截至 | 年 | 12 | 月 | 31 | 日 | | | （未经审计） | | | （经审计） | | | | | | | 资产总额 | | 273,191.13 | | 274,229.14 | | | | | | | 负债总额 | | - | | - | | | | | | | 其中：银行贷款总额 | | | - | - | | | | | | | 流动负债总额 | | - | | - | | | | | | | 净资产 | | 273,191.13 | | 274,229.14 | | | | | | | | | （未经审计） | | （经审计） | ...

Summary of Key Points Core Viewpoint - The financial data of Guangdong Loxin Medical Electronics Co., Ltd. indicates significant intercompany transactions and receivables, highlighting the company's operational dynamics and financial relationships with its subsidiaries and affiliates [1]. Group 1: Financial Relationships - The company has substantial receivables from its subsidiaries, including 17,094.55 million for sales products and 27,083.80 million for other receivables, indicating a strong operational interdependence [2]. - The total amount of intercompany receivables reported is 37,235.14 million, with a slight increase from the previous period [3]. Group 2: Subsidiary Performance - The subsidiary Zhongshan Loxin Electronics Co., Ltd. has reported receivables of 12,536.07 million for sales products, reflecting its role in the company's revenue generation [2]. - Other subsidiaries, such as Shenzhen Loxin Medical Electronics Co., Ltd., also show significant receivables, with amounts reaching 2,500.01 million for non-operational transactions [3]. Group 3: Operational Dynamics - The company’s financial statements reveal a mix of operational and non-operational transactions, with a clear distinction in the nature of receivables from different subsidiaries [2][3]. - The data suggests that the company is actively managing its financial relationships with its subsidiaries, which may impact its overall liquidity and operational efficiency [1].

为使投资者全面了解公司的经营情况和财务状况，公司《2025 年半年度报 告》及其摘要将于 2025 年 8 月 16 日在中国证监会指定的创业板信息披露网站巨 潮资讯网（www.cninfo.com.cn）披露，敬请投资者注意查阅。 特此公告。 广东乐心医疗电子股份有限公司 董事会 二〇二五年八月十六日 。 乐心医疗 2025 年公告 证券代码：300562 证券简称：乐心医疗 公告编号：2025-077 广东乐心医疗电子股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东乐心医疗电子股份有限公司（以下简称"公司"）于 2025 年 8 月 14 日 召开了第五届董事会第三次会议，审议通过了《关于<2025 年半年度报告全文> 及摘要的议案》 ...